{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:02:29Z","timestamp":1789783349119,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100014434","name":"Narodowa Agencja Wymiany Akademickiej","doi-asserted-by":"publisher","award":["BPN\/WAL\/2024\/1\/00057"],"award-info":[{"award-number":["BPN\/WAL\/2024\/1\/00057"]}],"id":[{"id":"10.13039\/501100014434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014434","name":"Narodowa Agencja Wymiany Akademickiej","doi-asserted-by":"publisher","award":["Decision No. SD\/2\/2025"],"award-info":[{"award-number":["Decision No. SD\/2\/2025"]}],"id":[{"id":"10.13039\/501100014434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014434","name":"Narodowa Agencja Wymiany Akademickiej","doi-asserted-by":"publisher","award":["June 11"],"award-info":[{"award-number":["June 11"]}],"id":[{"id":"10.13039\/501100014434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014434","name":"Narodowa Agencja Wymiany Akademickiej","doi-asserted-by":"publisher","award":["2025"],"award-info":[{"award-number":["2025"]}],"id":[{"id":"10.13039\/501100014434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004442","name":"Narodowym Centrum Nauki","doi-asserted-by":"publisher","award":["SONATA-2021\/43\/D\/NZ2\/02380"],"award-info":[{"award-number":["SONATA-2021\/43\/D\/NZ2\/02380"]}],"id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s00109-026-02718-1","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T01:07:45Z","timestamp":1789780065000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MicroRNA-122 as a regulator and biomarker of liver disease"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0499-2735","authenticated-orcid":false,"given":"Sara","family":"Ahmadova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia","family":"Wicik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Mucha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Palatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Zi\u0119tal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmara","family":"Mirowska-Guzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Przybylkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3324-9625","authenticated-orcid":false,"given":"Ceren","family":"Eyileten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"2718_CR1","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s11010-020-03988-0","volume":"476","author":"Z Yang","year":"2021","unstructured":"Yang Z, Wu W, Ou P et al (2021) MiR-122-5p knockdown protects against APAP-mediated liver injury through up-regulating NDRG3. Mol Cell Biochem 476:1257\u20131267","journal-title":"Mol Cell Biochem"},{"key":"2718_CR2","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/liv.12627","volume":"35","author":"C Roderburg","year":"2015","unstructured":"Roderburg C, Benz F, Vargas Cardenas D et al (2015) Elevated miR-122 serum levels are an independent marker of liver injury in inflammatory diseases. Liver Int 35:1172\u20131184","journal-title":"Liver Int"},{"key":"2718_CR3","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1017\/S0950268817001947","volume":"145","author":"SHI Hofstraat","year":"2017","unstructured":"Hofstraat SHI, Falla AM, Duffell EF et al (2017) Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU\/EEA: a systematic review. Epidemiol Infect 145:2873\u20132885","journal-title":"Epidemiol Infect"},{"key":"2718_CR4","doi-asserted-by":"publisher","first-page":"e47490","DOI":"10.1371\/journal.pone.0047490","volume":"7","author":"CN Hayes","year":"2012","unstructured":"Hayes CN, Akamatsu S, Tsuge M et al (2012) Hepatitis B virus-specific miRNAs and Argonaute2 play a role in the viral life cycle. PLoS One 7:e47490","journal-title":"PLoS One"},{"key":"2718_CR5","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1038\/onc.2009.211","volume":"28","author":"C Coulouarn","year":"2009","unstructured":"Coulouarn C, Factor VM, Andersen JB et al (2009) Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28:3526\u20133536","journal-title":"Oncogene"},{"key":"2718_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000519995","volume":"100","author":"N Akuta","year":"2022","unstructured":"Akuta N, Kawamura Y, Suzuki F et al (2022) Dynamics of circulating miR-122 predict liver cancer and mortality in Japanese patients with histopathologically confirmed NAFLD and severe fibrosis stage. Oncology (Williston Park) 100:31\u201338","journal-title":"Oncology (Williston Park)"},{"key":"2718_CR7","first-page":"e20240223","volume":"47","author":"RS da Cunha","year":"2025","unstructured":"da Cunha RS, Azevedo CAB, Miniskiskosky G et al (2025) MicroRNAs and vascular damage in chronic kidney disease: advances and clinical implications. J Bras Nefrol 47:e20240223","journal-title":"J Bras Nefrol"},{"key":"2718_CR8","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1172\/JCI63455","volume":"122","author":"W-C Tsai","year":"2012","unstructured":"Tsai W-C, Hsu S-D, Hsu C-S et al (2012) MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 122:2884\u20132897","journal-title":"J Clin Invest"},{"key":"2718_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s10020-019-0085-2","volume":"25","author":"J-K Long","year":"2019","unstructured":"Long J-K, Dai W, Zheng Y-W, Zhao S-P (2019) MiR-122 promotes hepatic lipogenesis via inhibiting the LKB1\/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. Mol Med 25:26","journal-title":"Mol Med"},{"issue":"7","key":"2718_CR10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.gastrohep.2022.12.003","volume":"46","author":"K Chen","year":"2023","unstructured":"Chen K, Lin T, Yao W, Chen X, Xiong X, Huang Z (2023) Adipocytes-derived exosomal miR-122 promotes non-alcoholic fat liver disease progression via targeting Sirt1. Gastroenterol Hepatol 46(7):531\u2013541","journal-title":"Gastroenterol Hepatol"},{"key":"2718_CR11","doi-asserted-by":"publisher","first-page":"e23937","DOI":"10.1371\/journal.pone.0023937","volume":"6","author":"S Cermelli","year":"2011","unstructured":"Cermelli S, Ruggieri A, Marrero JA et al (2011) Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 6:e23937","journal-title":"PLoS One"},{"key":"2718_CR12","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1111\/liv.12429","volume":"34","author":"H Miyaaki","year":"2014","unstructured":"Miyaaki H, Ichikawa T, Kamo Y et al (2014) Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int 34:e302\u2013e307","journal-title":"Liver Int"},{"key":"2718_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12876-016-0557-6","volume":"16","author":"N Akuta","year":"2016","unstructured":"Akuta N, Kawamura Y, Suzuki F et al (2016) Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma. BMC Gastroenterol 16:141","journal-title":"BMC Gastroenterol"},{"key":"2718_CR14","doi-asserted-by":"publisher","first-page":"e2300631","DOI":"10.1002\/ardp.202300631","volume":"357","author":"AM Samy","year":"2024","unstructured":"Samy AM, Kandeil MA, Sabry D et al (2024) Exosomal miR-122, miR-128, miR-200, miR-298, and miR-342 as novel diagnostic biomarkers in NAFL\/NASH: impact of LPS\/TLR-4\/FoxO3 pathway. Arch Pharm (Weinheim) 357:e2300631","journal-title":"Arch Pharm (Weinheim)"},{"key":"2718_CR15","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s13105-025-01110-w","volume":"81","author":"AL Tobaruela-Resola","year":"2025","unstructured":"Tobaruela-Resola AL, Milagro FI, Mogna-Pelaez P et al (2025) The use of circulating miRNAs for the diagnosis, prognosis, and personalized treatment of MASLD. J Physiol Biochem 81:589\u2013609","journal-title":"J Physiol Biochem"},{"key":"2718_CR16","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s13105-024-01037-8","volume":"81","author":"AL Tobaruela-Resola","year":"2025","unstructured":"Tobaruela-Resola AL, Milagro FI, Elorz M et al (2025) Circulating miR-122-5p, miR-151a-3p, miR-126-5p and miR-21-5p as potential predictive biomarkers for metabolic dysfunction-associated steatotic liver disease assessment. J Physiol Biochem 81:1275\u20131288","journal-title":"J Physiol Biochem"},{"key":"2718_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s43162-025-00511-z","author":"HM Nafeh","year":"2025","unstructured":"Nafeh HM, Abbas NM, El-Mokhtar MA et al (2025) Circulating microRNAs as potential non-invasive biomarkers for diagnosis and severity assessment of metabolic dysfunction-associated steatotic liver disease: a case\u2013control study. Egypt J Intern Med. https:\/\/doi.org\/10.1186\/s43162-025-00511-z","journal-title":"Egypt J Intern Med"},{"key":"2718_CR18","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1038\/ajg.2011.161","volume":"106","author":"V Bihrer","year":"2011","unstructured":"Bihrer V, Friedrich-Rust M, Kronenberger B et al (2011) Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol 106:1663\u20131669","journal-title":"Am J Gastroenterol"},{"key":"2718_CR19","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.bbrc.2010.07.021","volume":"398","author":"L Qiu","year":"2010","unstructured":"Qiu L, Fan H, Jin W et al (2010) MiR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV. Biochem Biophys Res Commun 398:771\u2013777","journal-title":"Biochem Biophys Res Commun"},{"key":"2718_CR20","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/hep.24809","volume":"55","author":"S Wang","year":"2012","unstructured":"Wang S, Qiu L, Yan X et al (2012) Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1) -modulated P53 activity. Hepatology 55:730\u2013741","journal-title":"Hepatology"},{"key":"2718_CR21","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1111\/j.1365-2893.2011.01443.x","volume":"18","author":"F Ji","year":"2011","unstructured":"Ji F, Yang B, Peng X et al (2011) Circulating microRNAs in hepatitis B virus-infected patients. J Viral Hepat 18:e242\u2013e251","journal-title":"J Viral Hepat"},{"key":"2718_CR22","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1096\/fj.11-187781","volume":"25","author":"Y Chen","year":"2011","unstructured":"Chen Y, Shen A, Rider PJ et al (2011) A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication. FASEB J 25:4511\u20134521","journal-title":"FASEB J"},{"key":"2718_CR23","doi-asserted-by":"publisher","first-page":"e0268526","DOI":"10.1371\/journal.pone.0268526","volume":"17","author":"A Ullah","year":"2022","unstructured":"Ullah A, Yu X, Odenthal M et al (2022) Circulating microRNA-122 in HCV cirrhotic patients with high frequency of genotype 3. PLoS One 17:e0268526","journal-title":"PLoS One"},{"key":"2718_CR24","doi-asserted-by":"publisher","first-page":"16338","DOI":"10.1021\/acs.jmedchem.2c01141","volume":"65","author":"C Emanuelson","year":"2022","unstructured":"Emanuelson C, Ankenbruck N, Kumbhare R et al (2022) Transcriptional inhibition of microRNA miR-122 by small molecules reduces hepatitis C virus replication in liver cells. J Med Chem 65:16338\u201316352","journal-title":"J Med Chem"},{"key":"2718_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.2174\/2211536609666201217101414","volume":"10","author":"J Moayedi","year":"2021","unstructured":"Moayedi J, Hashempour T, Musavi Z et al (2021) Evaluation of miR-122 serum level and IFN-\u03bb3 genotypes in patients with chronic HCV and HCV-infected liver transplant candidate. MicroRNA 10:58\u201365","journal-title":"MicroRNA"},{"key":"2718_CR26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40291-015-0148-1","volume":"19","author":"NE El-Abd","year":"2015","unstructured":"El-Abd NE, Fawzy NA, El-Sheikh SM, Soliman ME (2015) Circulating miRNA-122, miRNA-199a, and miRNA-16 as biomarkers for early detection of hepatocellular carcinoma in Egyptian patients with chronic hepatitis C virus infection. Mol Diagn Ther 19:213\u2013220","journal-title":"Mol Diagn Ther"},{"key":"2718_CR27","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1074\/jbc.M114.601203","volume":"290","author":"Q Wu","year":"2015","unstructured":"Wu Q, Liu H-O, Liu Y-D et al (2015) Decreased expression of hepatocyte nuclear factor 4\u03b1 (Hnf4\u03b1)\/microRNA-122 (miR-122) axis in hepatitis B virus-associated hepatocellular carcinoma enhances potential oncogenic GALNT10 protein activity. J Biol Chem 290:1170\u20131185","journal-title":"J Biol Chem"},{"key":"2718_CR28","doi-asserted-by":"publisher","first-page":"e28486","DOI":"10.1371\/journal.pone.0028486","volume":"6","author":"P Qi","year":"2011","unstructured":"Qi P, Cheng S-Q, Wang H et al (2011) Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One 6:e28486","journal-title":"PLoS One"},{"key":"2718_CR29","first-page":"742","volume":"21","author":"D-D Qiao","year":"2017","unstructured":"Qiao D-D, Yang J, Lei X-F et al (2017) Expression of microRNA-122 and microRNA-22 in HBV-related liver cancer and the correlation with clinical features. Eur Rev Med Pharmacol Sci 21:742\u2013747","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2718_CR30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mc.20712","volume":"50","author":"J Xu","year":"2011","unstructured":"Xu J, Wu C, Che X et al (2011) Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 50:136\u2013142","journal-title":"Mol Carcinog"},{"key":"2718_CR31","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1128\/JVI.02831-12","volume":"87","author":"C Li","year":"2013","unstructured":"Li C, Wang Y, Wang S et al (2013) Hepatitis B virus mRNA-mediated miR-122 inhibition upregulates PTTG1-binding protein, which promotes hepatocellular carcinoma tumor growth and cell invasion. J Virol 87:2193\u20132205","journal-title":"J Virol"},{"key":"2718_CR32","first-page":"1281","volume":"26","author":"C-G Fan","year":"2011","unstructured":"Fan C-G, Wang C-M, Tian C et al (2011) miR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3. Oncol Rep 26:1281\u20131286","journal-title":"Oncol Rep"},{"key":"2718_CR33","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12967-016-0956-z","volume":"14","author":"Y-C Shyu","year":"2016","unstructured":"Shyu Y-C, Lee T-L, Lu M-J et al (2016) MiR-122-mediated translational repression of PEG10 and its suppression in human hepatocellular carcinoma. J Transl Med 14:200","journal-title":"J Transl Med"},{"key":"2718_CR34","doi-asserted-by":"publisher","first-page":"e76867","DOI":"10.1371\/journal.pone.0076867","volume":"8","author":"C Spaniel","year":"2013","unstructured":"Spaniel C, Honda M, Selitsky SR et al (2013) MicroRNA-122 abundance in hepatocellular carcinoma and non-tumor liver tissue from Japanese patients with persistent HCV versus HBV infection. PLoS ONE 8:e76867","journal-title":"PLoS ONE"},{"key":"2718_CR35","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1002\/hep.22749","volume":"49","author":"S Ura","year":"2009","unstructured":"Ura S, Honda M, Yamashita T et al (2009) Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma#. Hepatology 49:1098","journal-title":"Hepatology"},{"key":"2718_CR36","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/hep.26514","volume":"58","author":"K Song","year":"2013","unstructured":"Song K, Han C, Zhang J et al (2013) Epigenetic regulation of microRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis B virus X protein in hepatocellular carcinoma cells. Hepatology 58:1681\u20131692","journal-title":"Hepatology"},{"key":"2718_CR37","first-page":"1438","volume":"24","author":"MB Keingeski","year":"2025","unstructured":"Keingeski MB, Longo L, da Silva Pinto A et al (2025) Extracellular vesicles and microRNAs in metabolic dysfunction-associated steatotic liver disease: from steatosis to hepatocellular carcinoma. EXCLI J 24:1438\u20131455","journal-title":"EXCLI J"},{"key":"2718_CR38","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1186\/s12967-024-05901-5","volume":"22","author":"S Dai","year":"2024","unstructured":"Dai S, Zhuang H, Li Z et al (2024) MiR-122\/NEGR1 axis contributes colorectal cancer liver metastasis by PI3K\/AKT pathway and macrophage modulation. J Transl Med 22:1060","journal-title":"J Transl Med"},{"key":"2718_CR39","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","volume":"368","author":"HLA Janssen","year":"2013","unstructured":"Janssen HLA, Reesink HW, Lawitz EJ et al (2013) Treatment of HCV infection by targeting microRNA. N Engl J Med 368:1685\u20131694","journal-title":"N Engl J Med"},{"key":"2718_CR40","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1128\/AAC.04220-14","volume":"59","author":"S Ottosen","year":"2015","unstructured":"Ottosen S, Parsley TB, Yang L et al (2015) In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrob Agents Chemother 59:599\u2013608","journal-title":"Antimicrob Agents Chemother"},{"key":"2718_CR41","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(16)31715-9","volume":"389","author":"MH van der Ree","year":"2017","unstructured":"van der Ree MH, de Vree JM, Stelma F et al (2017) Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial. Lancet 389:709\u2013717","journal-title":"Lancet"},{"key":"2718_CR42","doi-asserted-by":"publisher","first-page":"721","DOI":"10.2147\/DDDT.S288859","volume":"15","author":"S Zhang","year":"2021","unstructured":"Zhang S, Cheng Z, Wang Y, Han T (2021) The risks of miRNA therapeutics: in a drug target perspective. Drug Des Devel Ther 15:721\u2013733","journal-title":"Drug Des Devel Ther"},{"key":"2718_CR43","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev-virology-110615-042409","volume":"3","author":"P Sarnow","year":"2016","unstructured":"Sarnow P, Sagan SM (2016) Unraveling the mysterious interactions between hepatitis C virus RNA and liver-specific MicroRNA-122. Annu Rev Virol 3:309\u2013332","journal-title":"Annu Rev Virol"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-026-02718-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-026-02718-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-026-02718-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T01:07:46Z","timestamp":1789780066000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-026-02718-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["2718"],"URL":"https:\/\/doi.org\/10.1007\/s00109-026-02718-1","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Patient consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"110"}}